Aster Capital Management (DIFC) Ltd
Position in TRVI — Trevi Therapeutics, Inc.
CIK 2040915
DUBAI, C0
Position in TRVI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$7,777
+$240 QoQ
Shares Held
417
-30.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#192
of 216 holders
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in TRVI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Aster Capital Management (DIFC) Ltd holds $13,611,362 across 52 Biotechnology names. TRVI ranks #39 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,302 | $3,130,392 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,374 | $1,480,283 | |
| 3 | INSM |
INSMED Inc
|
11,814 | $1,259,608 | |
| 4 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
12,667 | $1,032,487 | |
| 5 | INCY |
Incyte Corp
|
7,433 | $842,604 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
9,491 | $706,889 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
2,457 | $601,399 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
8,988 | $514,293 |
All Filings in TRVI
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,777 | 417 | Shares | Sole | 2026-08-14 | |
| 2025-12-31 | $7,537 | 602 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||